[Effects of etoposide in testicular tumors].

Abstract

A clinical study of a new semisynthetic podophyllotoxin etoposide (NK 171) was performed by administering the drug to four patients with testicular tumors. The drug was given intravenously at a dose of 80-120 mg/m2/day for five days or orally at a dose of 200 mg/body/day for five days. Among the four patients, 1 CR, 1 NC and 2 PD were observed. One patient with a testicular tumor who was given oral etoposide achieved complete remission for 23 months. Patients experienced the following side effects: alopecia (75%); anorexia (50%): stomatitis, phlebitis, anemia and liver dysfunction (25%). None of these side effects, however, was serious or permanent. Currently, we are testing etoposide in combination chemotherapy.

• Authors: T Tanahashi, Y Matsumura, Y Ozaki, J Yoshimoto, T Tsushima, T Obama, T Akagi, Y Nasu, H Ohmori
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 13 Issue 10 Pg. 3074-7 (Oct 1986) ISSN: 0385-0684 [Print] Japan
• PMID: 3767390 (Publication Type: English Abstract, Journal Article)

Chemical References

• Etoposide

Topics

• Administration, Oral
• Adult
• Drug Evaluation
• Dysgerminoma (drug therapy)
• Etoposide (administration & dosage, therapeutic use)
• Humans
• Infusions, Intravenous
• Male
• Teratoma (drug therapy)
• Testicular Neoplasms (drug therapy)